Objective: This network meta-analysis compared overall survival after neoadjuvant or adjuvant chemotherapy (CT), radiotherapy (RT), or combinations of both (chemoradiotherapy, CRT) or surgery alone to identify the most effective approach. Summary Background Data: The optimal treatment for resectable esophageal cancer is unknown. Methods: A search for randomized controlled trials reporting on neoadjuvant and adjuvant therapies was conducted. Using a network meta-analysis, treatments were ranked based on their effectiveness for improving survival. Results: In 33 eligible randomized controlled trials, 6072 patients were randomized to receive either surgery alone (N ¼ 2459) or neoadjuvant CT (N ¼ 1332), RT (N ¼ 58), and CRT (N ¼ 1196) followed by surgery or surgery followed by adjuvant CT (N ¼ 542), RT (N ¼ 383), and CRT (N ¼ 102). Twenty-one comparisons were generated. Neoadjuvant CRT followed by surgery compared with surgery alone was the only treatment to significantly improve survival [hazard ratio (HR) ¼ 0.77, 95% confidence interval (CI): 0.68-0.87]. When trials were grouped considering neoadjuvant and adjuvant therapies and surgery alone, neoadjuvant therapies combined with surgery compared with surgery alone showed a survival advantage (HR ¼ 0.83, 95% CI 0.76-0.90), whereas surgery along with adjuvant therapies showed no significant survival advantage (HR ¼ 0.87, 95% CI 0.67-1.14). A subgroup analysis of neoadjuvant therapies showed a superior effectiveness of neoadjuvant CRT and surgery compared with surgery alone (HR ¼ 0.77, 95% CI 0.68-0.87). Conclusions: This network meta-analysis showed neoadjuvant CRT followed by surgery to be the most effective strategy in improving survival of resectable esophageal cancer. Resources should be focused on developing the most effective neoadjuvant CRT regimens for both adenocarcinomas and squamous cell carcinomas of the esophagus.
S
urvival from esophageal cancer remains poor. 1, 2 Patients with resectable esophageal cancer have an overall 5-year survival between 15% and 25%. 3, 4 Although surgery is the mainstay of potentially curative treatment, 5 neoadjuvant or adjuvant therapies have been shown in selected patients to improve survival. These can be administered as chemotherapy (CT), radiotherapy (RT), or synchronous chemoradiotherapy (CRT). 6, 7 Currently, the optimal timing, schedules, and dosing of CT, RT, or CRT are all still unclear. 8 Randomized controlled trials (RCT) and meta-analyses comparing the survival benefits of both CT and RT in both the adjuvant and neoadjuvant settings have reported contrasting and sometimes equivocal results. 5, [9] [10] [11] [12] [13] A previous meta-analysis compared only neoadjuvant CRT and neoadjuvant CT with surgery alone, showing both significantly reduced the risk of death by 22% and 13%, respectively. 12 Neoadjuvant CT and neoadjuvant CRT are yet to be compared in a well-powered clinical RCT, with 2 recent trials closing before complete accrual. 14, 15 From the adjuvant perspective, RT and CT have been shown to improve local control and possibly survival in selected groups such as patients with lymph node positive disease. 2, 5 Eligibility for adjuvant therapies is, however, limited by patient fitness, especially in those who have prolonged postoperative recovery. 16 Since the publication of the most recent meta-analysis 12 4 trials [17] [18] [19] [20] enrolling almost 1100 patients have reported conflicting results. In addition, the latest meta-analyses only addressed neoadjuvant therapies. This diverse evidence allows for an opportunity to compare the various interventions using a network meta-analysis, that is, adjuvant and neoadjuvant treatments with CT, RT, or CRT, by using a common reference that is part of all the RCTs, that is, surgery alone. The advantage of this approach over conventional direct metaanalysis is that it allows the evaluation of treatments that have not been compared directly or indirectly (eg, comparison of B vs C, using data from trials comparing A vs B and A vs C); it ranks multiple treatments based simultaneously on their efficacy; and it pools together direct and indirect evidence within mixed comparisons improving the precision of estimates. 21, 22 The study aimed to perform a network meta-analysis comparing overall survival for adjuvant and neoadjuvant CT, RT, and CRT in patients with resectable esophageal cancer.
METHODS

Literature Search
The protocol of this meta-analysis was registered with the prospective register of systematic reviews, PROSPERO (identification code CRD42015015820).
A systematic review of RCTs reporting on the efficacy of adjuvant and neoadjuvant therapies for patients undergoing surgery From the The following analysis were performed: comparison of all identified treatment modalities; comparison of treatment modalities grouped as neoadjuvant treatments, adjuvant treatments, and surgery alone; comparison of neoadjuvant CRT, neoadjuvant CT, and surgery alone; and a subgroup analysis based on histological type. Analyses 1 and 4 were prespecified in the protocol, whereas analyses 2 and 3 are post hoc.
A search of Embase, Ovid MEDLINE, and the Cochrane library was conducted by 2 investigators (G.Y. and S.P.) using the medical subject headings search terms: [''esophageal neoplasms'' OR (''esophagogastric junction'' AND ''neoplasms'')] AND (''chemotherapy'' OR ''radiotherapy'') AND (''neoadjuvant therapy'' OR ''adjuvant therapy'') AND (''surgery'' OR ''esophagectomy''). The searches were limited to articles describing RCTs published in English. The time period was up to January 2016. Manual searching of reference lists from original articles and previous meta-analyses was also performed.
Only full-text articles were included; if multiple publications of the same trial were retrieved, the most recent and informative publication was included. Studies enrolling patients with gastric and gastroesophageal cancer were excluded when data for esophageal cancer were not separately extractable and/or the study included limited number of patients with esophageal cancer (<20%).
The abstracts were reviewed by 2 investigators (P.M./R.S.V.) and conflicts resolved by the senior author (E.A.G.).
Risk of Bias Assessment
All articles were assessed for risk of bias by D.N. and S.P. using the Cochrane Risk of bias tool for RCTs. 25 Included RCTs were classified into 1 of 3 categories: low risk, high risk, or unclear risk. The data were extracted by G.Y. and S.P. using predefined data fields. The extracted data were verified independently (S.M.).
Evidence Grading
The Grading of Recommendation, Assessment, Development and Evaluation system adapted to network meta-analysis was employed to grade the quality of evidence into 4 levels: high, moderate, low, and very low quality. 26 The quality can be downgraded by 1 (serious concern) or 2 levels (very serious concern) for the following reasons: study limitations (risk of bias, see above paragraph), evidence for publication bias (as assessed by means of a funnel plot dedicated to network meta-analysis), 27 indirectness (indirect population, intervention, control, outcomes, lack of transitivity assumption, see below), inconsistency (between-study statistical heterogeneity, as suggested prediction intervals crossing the unit), and imprecision (confidence intervals crossing the unit, single trial).
Statistical Analysis
The study endpoint was overall survival and the outcome measure was the hazard ratio (HR) with its 95% confidence interval (CI). When HRs were not available, they were estimated using the method described by Parmar et al. 28 For direct comparisons, standard pairwise meta-analysis was performed using the inverse variance DerSimonian-Laird random effects model. 29 If a direct comparison was based on 2 or more studies, between-study heterogeneity, which represents the extent of variation among the intervention effects observed in different studies is the variance of the effect size parameters across the population of studies, was quantified using the I-squared statistic. Heterogeneity was considered low, moderate, or high for I-squared values <25%, 25% to 50%, and >50%, respectively. 30 Random effects network meta-analysis was carried out within a frequentist setting. 31, 32 A common heterogeneity parameter (tausquared) was assumed across all comparisons, allowing the inclusion of comparisons based on a single RCT. Each summary effect is presented along with its 95% CI and predictive interval. The latter is calculated using the between-study variance tau-squared and represents the interval where the results future studies are expected to be, and thus providing information on the magnitude of heterogeneity.
The key assumption of network meta-analysis is transitivity. 33 For example, if information is available comparing A versus B and A versus C, then network meta-analysis can derive information regarding the B versus C comparison based on the transitivity equation (A vs B -A vs C ¼ B vs C). The transitivity assumption assumes that a common treatment (resectional surgery in this case) is used, and is reasonably consistent amongst all the studies; all pairwise comparisons do not differ substantially with respect to the distribution of effect modifiers; and participants, could in principle, be randomized to any of the treatments being compared in the network. Lack of transitivity can manifest as inconsistency between direct and indirect estimates (loop inconsistency) or between estimates deriving from different study designs (design inconsistency). Inconsistency has been investigated using a design-by-treatment interaction model, which addresses both loop and design inconsistencies. 34, 35 Network meta-analysis also provides a ranking probability curve of each treatment (rankogram) by calculating the probability of each arm achieving the best rank amongst all treatments. The surface under the cumulative ranking (SUCRA) line for each treatment, which equals 1 when a treatment is certain to be the best and 0 when a treatment is certain to be the worst, was used for treatment ranking. 27, 36 All statistical tests were 2-sided. Statistical analysis and graph generation were performed with Stata 11.2 (StataCorp, College Station, TX). Risk of bias was assessed using the dedicated Cochrane tool of Review Manager (RevMan, version 5.1, The Nordic Cochrane Centre: The Cochrane Collaboration, Copenhagen, Norway).
RESULTS
A total of 34 articles were eligible ( Fig. 1) . 3,14,15,17 -20,37-63 Trials compared the following treatments: surgery alone, surgery with neoadjuvant CT, surgery with neoadjuvant CRT, surgery with adjuvant RT, surgery with adjuvant CT, and surgery with adjuvant CRT (Network plot, Fig. 2 ). The main features of these studies are reported in Table 1 . In one study of 237 patients, 38 HR was neither provided nor extractable from survival curves according to the Parmar's method 28 and attempts to contact the manuscript author failed. Therefore, the present study was excluded leaving a total of 33 RCTs. Some 6072 patients were randomized to receive either surgery alone (N ¼ 2459) or neoadjuvant CT (N ¼ 1332), RT (N ¼ 58), and CRT (N ¼ 1196) followed by surgery or surgery followed by adjuvant CT (N ¼ 542), RT (N ¼ 383), and CRT (N ¼ 102).
Direct Comparison Meta-analysis
Results of single RCTs and standard pairwise meta-analysis of direct comparisons are fully reported in Supplementary Materials (Supplementary Table 1 Network meta-analysis results were consistent with those from standard pairwise meta-analysis ( Fig. 3 ) again demonstrating a greater efficacy for neoadjuvant therapies along with surgery compared with adjuvant therapies. Among 21 comparisons, neoadjuvant CRT along with surgery versus surgery alone was the only statistically significant comparison (summary HR ¼ 0.77, CI: 0.68-0.87; P < 0.001).
There was no evidence of violation of the transitivity assumption, based on the observations that the common treatment (surgery) was reasonably consistent across trials, effect modifiers were equally distributed across studies, and participants could in principle be randomized to any of the treatments being compared in the network. Finally, the design-by-treatment interaction model showed no evidence of statistically significant inconsistency (P ¼ 0.856).
Ranking analysis performed with SUCRA, a simple transformation of the mean rank used to provide a hierarchy of the treatments, showed neoadjuvant therapies followed by surgery ranking higher than surgery followed by adjuvant treatments. Neoadjuvant CT (0.76) and CRT (0.74) ranked first and second, respectively, although the SUCRA difference was small. Subsequently, the other treatments were ranked as follows: neoadjuvant RT along with surgery (0.60), surgery along with adjuvant CT (0.45), surgery along with adjuvant CRT (0.42), and surgery along with adjuvant RT (0.34).
Adjuvant Versus Neoadjuvant Therapies
An analysis was conducted grouping together neoadjuvant therapies along with surgery and adjuvant therapies compared with surgery alone. Network meta-analysis showed a survival advantage with neoadjuvant therapies along with surgery compared with surgery alone (HR ¼ 0.83, 95% CI 0.76-0.90, P < 0.001). Surgery along with adjuvant therapies showed no survival advantage when compared with surgery alone (HR ¼ 0.87, 95% CI 0.67-1.14, P ¼ 0.321). Ranking analysis revealed that neoadjuvant therapies along with surgery was superior treatment followed by surgery along with adjuvant treatments then surgery alone (SUCRA values 0.82, 0.59, and 0.08, respectively).
Neoadjuvant Chemotherapy Versus Chemoradiotherapy
Network meta-analysis was used to search for survival differences between patients who underwent neoadjuvant CRT along with surgery, neoadjuvant CT along with surgery, and surgery alone. Patients who underwent neoadjuvant CRT along with surgery 
Squamous Cell Carcinoma and Adenocarcinoma
Subgroup analysis for squamous cell carcinoma (SCC) and adenocarcinoma was conducted in 27 trials. Subgroup analysis for SCC and adenocarcinoma when neoadjuvant, adjuvant treatments, and surgery alone were compared showed similar results. Again analysis was limited to SCC for the same reason mentioned above.
Finally, subgroup analysis was conducted for 23 and 10 trials investigating neoadjuvant CRT and CT in SCC 3,17,18,20,37,39,41 -45,47-56,59,60 and adenocarcinoma, 3, 14, 15, 17, 18, 20, 45, 47, 59, 61 respectively. Neoadjuvant CRT was associated with better survival in SCC (HR ¼ 0.80, 95% CI 0.69-0.92, P ¼ 0.002), whereas neoadjuvant CT showed a borderline (HR ¼ 0.89, 95% CI 0.79-1.00, P ¼ 0.051). Neoadjuvant CRT along with surgery ranked first (SUCRA analysis 0.83) followed by neoadjuvant CT along with surgery (0.17) and surgery alone (0.0).
In patients with adenocarcinoma, neoadjuvant CRT along with surgery was associated with a survival advantage over surgery alone (HR ¼ 0.76, 95% CI 0.61-0.94, P ¼ 0.013), but not with neoadjuvant CT (HR ¼ 0.93, 95% CI 0.76-1.14, P ¼ 0.483). Neoadjuvant CRT along with surgery ranked first (SUCRA analysis 0.88), followed by neoadjuvant CT along with surgery (0.24) and surgery alone (0.01).
Quality Assessment of Trials and Evidence Grading
None of the eligible RCTs presented a severe risk of bias (Supplementary Table 2 , http://links.lww.com/SLA/B62). Also, funnel plot analysis did not indicate any evident risk of publication bias ( Supplementary Fig. 2 , http://links.lww.com/SLA/B62). These findings, coupled with the absence of inconsistency and the lack of violation of the transitivity assumption, allowed to grade as high the strength of evidence advocating neoadjuvant CRT along with surgery a better treatment than surgery alone.
All the other treatment comparisons were characterized by a confidence interval crossing the null value. Accordingly, their strength of evidence was graded as moderate.
DISCUSSION
This is the first analysis to compare neoadjuvant therapy versus adjuvant therapy versus surgery alone for resectable esophageal cancer. The results provide evidence of a survival advantage of neoadjuvant CRT compared with neoadjuvant CT, adjuvant CT, adjuvant RT or surgery alone. This is supported through the use of 3 separate analyses and a consistent finding encompassing both SCC and adenocarcinoma of the esophagus.
Neoadjuvant Therapies
The evidence currently suggests the optimal treatment for resectable esophageal cancer should include neoadjuvant therapy followed by surgery rather than surgery alone or surgery followed by adjuvant therapy. 12 In the current meta-analysis results from the recent CROSS 18, 64 and FFCD 9901, 17 which investigated the efficacy of neoadjuvant CRT along with surgery compared with surgery alone, were included. The CROSS trial compared neoadjuvant CRT along with surgery with surgery alone and demonstrated that neoadjuvant CRT improved both locoregional control and distant metastasis-free survival. 18 The FFCD 9901 also compared neoadjuvant CRT along with surgery with surgery alone in patients with stage I-II disease. Initially the study recruitment was amended before being stopped early as an interim analysis demonstrated that the neoadjuvant CRT along with surgery arm was unlikely to show superiority. 17 In contrast to previous meta-analysis, 12 the risk reduction of death associated with neoadjuvant CT along with surgery was not statistically significant. The previous meta-analysis did not include Baba et al, 37 an RCT conducted in 42 patients with SCC, but included Ychou et al, 65 which also enrolled patients with gastric cancer. Neoadjuvant CT seemed to be associated with a poorer but a nonsignificant survival advantage compared with neoadjuvant CRT (HR ¼ 1.16, 95% CI 0.98-1.38, Fig. 3) . Again, when neoadjuvant CRT and CT were compared with surgery alone in a subgroup analysis, neoadjuvant CRT ranked first (97% probability vs 54% probability for CT). Using the Grades of Recommendation, Assessment, Development and Evaluation system, evidence for effectiveness of neoadjuvant CRT along with surgery over neoadjuvant CT along with surgery was downgraded from high to moderate, as the CI crossed the unit. 26 Currently, a randomized trial of neoadjuvant and adjuvant CT (modified MAGIC regimen) compared with neoadjuvant CRT (CROSS protocol) in adenocarcinoma of the esophagus and esophagogastric junction (Neo-AEGIS trial) is underway in the United Kingdom and Ireland. 66 Until the results are available, the data presented here support neoadjuvant CRT and recruitment into such a trial. 
Adjuvant Therapies
Adjuvant therapies appeared lesser effective compared with the neoadjuvant approaches (Fig. 3 ) and did not improve survival when compared with surgery alone. Also they ranked after neoadjuvant therapies both in the overall analysis and when different neoadjuvant and adjuvant therapies were grouped together. Adjuvant therapies may provide a survival benefit in lymph node-positive patients 5, 7 ; however, this has not been investigated in a formal RCT. With the more convincing benefit of neoadjuvant therapies described here and previously, it is unlikely that adjuvant therapies will be tested again.
Squamous Cell Carcinoma and Adenocarcinoma
Subgroup analysis showed neoadjuvant CRT and, to a lesser extent, neoadjuvant CT are effective and superior to adjuvant therapies for improving survival of patients with SCC. The group of patients with adenocarcinoma cannot be investigated for lack of RCTs addressing adjuvant therapy in these patients. When only neoadjuvant therapies were considered in patients with adenocarcinoma, neoadjuvant CRT, however, had a better survival compared with surgery alone. Again this survival benefit was not seen when neoadjuvant CT was administered.
Limitations
This present study is acknowledged to have several limitations. The RCTs were conducted over 3 decades and changes in RT planning and delivery, CT drugs, and schedules are likely to affect the results. In addition, staging modalities and surgical techniques have advanced. Although, transitivity assumption was met and there was no evidence of statistically significant inconsistency in this network meta-analysis, the accuracy of our results (such as that for neoadjuvant chemotherapy) can be tempered by differences in CT and/or RT regimens across studies. 67 Systematic review and network meta-analysis were limited to patients with esophageal carcinoma. As a result, important trials, such as MAGIC 68 and FFCD, 65 which investigated perioperative treatment in gastric, gastroesophageal, and lower esophagus cancer, were excluded. This highlights the challenges in defining tumors of the upper gastrointestinal tract. 69 Although both neoadjuvant and adjuvant therapies have been included here to offer a comprehensive overview and an attempt to compare the overall survival of both strategies, these treatments have different toxicity and safety profiles and prevent a formal comparison of morbidity. A recent meta-analysis has, however, shown a greater morbidity associated with neoadjuvant CRT FIGURE 3. Network meta-analysis results: efficacy of five treatment modalities as compared to surgery (S) alone. The treatment effect measure is expressed as hazard ratio. ACRT indicates adjuvant chemoradiotherapy; ACT, adjuvant chemotherapy; ART, adjuvant radiotherapy; NCRT, neoadjuvant chemoradiotherapy; NCT, neoadjuvant chemotherapy; NRT, neoadjuvant radiotherapy; PrI, predictive interval; S, surgery. compared with neoadjuvant CT for patients with SCC. 70 Two ongoing trials (NCT01726452 and NCT02359968) will address which neoadjuvant therapy is superior in terms of survival, morbidity, quality of life, and costs. No RCTs investigating adjuvant therapies in adenocarcinoma were identified, so an analysis of adjuvant therapies and histological type is not presented. The inclusion of adenocarcinoma into some trials and inclusion of early-stage tumors in some studies, for example, 63 patients with T1-T2 tumors represent 17% of the cohort in the CROSS trial, 18 may confound the results. In the networked analysis presented here, there are limited numbers of low-risk patients (T1/T2 tumors) enrolled in RCTs considered. These findings cannot therefore be generalized to the treatment of these early stage disease. Finally, the role of definitive CRT was not considered here and it should be noted that there is evidence that definitive CRT without surgery, particularly in SCC may potentially be equivalent to surgery alone in overall survival and health-related quality of life. 67, 71, 72 
CONCLUSIONS
The uncertainty of the optimal timing, schedules, and dosing of CT, RT, or CRT has led to regional variability in the use of multimodality therapy in esophageal cancer. For example, adjuvant CT is preferred in China and Japan, 73 whereas in the United States, neoadjuvant CRT is the accepted standard of care and the consensus in the UK supports neoadjuvant CT. 74 This network meta-analysis has allowed the comparison of treatments not directly compared before and indicated a survival advantage conferred by neoadjuvant CRT. Therefore, resources should be focused on developing the most effective neoadjuvant CRT regimens for both adenocarcinomas and squamous cell carcinomas of the esophagus.
